GlucoVantage dihydroberberine at 200mg may produce fewer GI symptoms than standard berberine because of its improved bioavailability
The study proceeded in three phases: emulation of the SUSTAIN-6 and SURPASS-CVOT trials, expansion to real-world cohorts, and a direct comparison between tirzepatide and semaglutide
Abstract The paradigm of one drug against multiple targets, known as unimolecular polypharmacology, offers the potential to improve efficacy while overcoming some adverse events associated with the treatment
If you are losing muscle, the answer is protein and resistance training, not a stronger drug
Tirzepatide is ideal for adults in Tigard who are overweight or obese and have not seen satisfactory results with diet and exercise
If patients do not tolerate a dose during dose escalation, consider delaying dose escalation